TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18048822

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 804

Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Both groups (high-dose and conventional-dose chemotherapy)
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Patients with lower educational level and many complaints before chemotherapy
Number of subjects: 804
Study: 16214509

Group type: EXPERIMENTAL
Intervention: Intercostal muscle flap
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard posterior-lateral thoracotomy
Number of subjects: 114
Study: 15493239

Group type: EXPERIMENTAL
Intervention: Highly explicit, teacher-directed instructional routine teaching three planning strategies (goal setting, brainstorming, organizing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highly explicit, teacher-directed instructional routine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Process writing instruction (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Highly explicit, teacher-directed strategy instructional routine
Number of subjects: 0
Study: 10102174

Group type: EXPERIMENTAL
Intervention: Preconception counseling addressing nutrition, prevention and prediction of preeclampsia, prenatal visits, fetal surveillance, risk of superimposed preeclampsia, recurrence risks, diagnosis of underlying factors, and impact on maternal and fetal health.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reviewing existing literature with patients in a nondirective manner and providing prenatal care.
Number of subjects: 0
Study: 7755941

Group type: EXPERIMENTAL
Intervention: 120 mg verapamil (V) twice a day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1 mg terazosin (T) titrated weekly to 5 mg daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination therapy (T added to V or V added to T)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Combination therapy (group TV)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Combination therapy (group VT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination therapy (T and V)
Number of subjects: 24
Study: 2233205

Group type: EXPERIMENTAL
Intervention: TM-Rel (Treadmill at relative VO2)
Number of subjects: 8
Study: 37190

Group type: EXPERIMENTAL
Intervention: acebutolol hydrochloride (SECTRAL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 29903889

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) kits provided to patients, encouraged to report results to I Want the Kit (IWTK), and received referral cards for peers.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group received pamphlets about publicly available HIV testing sites.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) kits provided to patients.
Number of subjects: 100
Study: 29084336

Group type: EXPERIMENTAL
Intervention: s-lactam monotherapy
Number of subjects: 1418

Group type: COMPARATOR
Intervention: s-lactam plus macrolide combination therapy
Number of subjects: 1418
Study: 26114161

Group type: EXPERIMENTAL
Intervention: Experimental therapy (bevacizumab)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571
Study: 23897998

Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol B
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rehabilitation protocol A
Number of subjects: 40
Study: 21723554

Group type: EXPERIMENTAL
Intervention: Active tablets containing 3.4 mg of VPP and IPP
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 70
Study: 18986246

Group type: COMPARATOR
Intervention: C-ART
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: 2/4-ART
Number of subjects: 435
Study: 16752625

Group type: EXPERIMENTAL
Intervention: Mandibular overdentures retained by 2 endosseous implants
Number of subjects: 151

Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 151
Study: 14998097

Group type: EXPERIMENTAL
Intervention: Equipment group (SAQ with specialized equipment)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Non-equipment group (SAQ with traditional equipment)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Active control group (regular fitness sessions)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Equipment group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Non-equipment group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 36
Study: 11544566

Group type: EXPERIMENTAL
Intervention: Dynotest TRAK human assay
Number of subjects: 21

Group type: COMPARATOR
Intervention: Porcine TBII assay
Number of subjects: 21
Study: 9763796

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 2% Lactate
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 8% CHO
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 8% CHO + 2% Lactate
Number of subjects: 7
Study: 10406437

Group type: EXPERIMENTAL
Intervention: Interactive brochure designed using the Motivation Generating model (Calcium CalculatorS)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Calcium information brochure (An Appetite for Good Health)
Number of subjects: 216
Study: 2239124

Group type: EXPERIMENTAL
Intervention: 10 mg bambuterol
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 20 mg bambuterol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 329077

Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato-bismuthate (TDB)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 30025414

Group type: EXPERIMENTAL
Intervention: 1L PEG NER1006 (N2D regimen)
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: 1L PEG NER1006 (N1D regimen)
Number of subjects: 849

Group type: COMPARATOR
Intervention: 2L polyethylene glycol + ascorbate (2LPEG)
Number of subjects: 849
Study: 28760818

Group type: EXPERIMENTAL
Intervention: Standard haematological care associated with palliative care (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard haematological care with palliative care only if requested by the haematologist (control group)
Number of subjects: 0
Study: 26530543

Group type: EXPERIMENTAL
Intervention: Physical activity counseling (telephone contacts 3 times a week with real-time feedback)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study: 23378769

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg once daily
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 21195291

Group type: EXPERIMENTAL
Intervention: Carthami-Semen (CS) acupuncture point injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (NS) acupuncture point injection
Number of subjects: 40
Study: 19446152

Group type: EXPERIMENTAL
Intervention: Clopidogrel besylate (300 mg loading dose, 75 mg/d maintenance dose)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Clopidogrel bisulfate (300 mg loading dose, 75 mg/d maintenance dose)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both clopidogrel preparations
Number of subjects: 44
Study: 16805721

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn insulin (NPH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin ultralente
Number of subjects: 0
Study: 15628250

Group type: EXPERIMENTAL
Intervention: Deep Relief gel with sonophoresis
Number of subjects: 130

Group type: COMPARATOR
Intervention: Ultrasound with standard gel
Number of subjects: 130
Study: 11316646

Group type: EXPERIMENTAL
Intervention: 4 mg NCS
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 8 mg NCS
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 14
Study: 9252710

Group type: EXPERIMENTAL
Intervention: Lentinan administration
Number of subjects: 0
Study: 7514863

Group type: EXPERIMENTAL
Intervention: Transbronchial biopsy
Number of subjects: 12
Study: 2531608

Group type: EXPERIMENTAL
Intervention: Cilazapril (5 mg p.o.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg p.o.)
Number of subjects: 6
Study: 31090212

Group type: EXPERIMENTAL
Intervention: Healthcare resource utilization (HRU)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Supportive therapy utilization (STU)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Common reasons for hospitalization
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Common reasons for surgery
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Commonly prescribed drugs
Number of subjects: 302
Study: 28854067

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus ipilimumab
Number of subjects: 956

Group type: COMPARATOR
Intervention: Chemotherapy plus placebo
Number of subjects: 956
Study: 26305052

Group type: EXPERIMENTAL
Intervention: Resveratrol 75 mg twice daily for 30 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo twice daily for 30 days
Number of subjects: 20
Study: 23686786

Group type: EXPERIMENTAL
Intervention: Caffeine/Ephedrine (200 mg caffeine/20 mg ephedrine t.i.d.)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination Leptin A‐200 and Caffeine/Ephedrine (Leptin A‐200 20 mg q.d. + Caffeine/Ephedrine)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Leptin A‐200 (20 mg q.d.)
Number of subjects: 90
Study: 21320959

Group type: EXPERIMENTAL
Intervention: Subfoveal serous retinal detachment (SRD) group
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (without SRD)
Number of subjects: 98
Study: 18692817

Group type: EXPERIMENTAL
Intervention: Neutralizing target cytokines
Number of subjects: 0
Study: 17159824

Group type: EXPERIMENTAL
Intervention: Oral estrogen therapy (2 mg daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Transdermal estrogen therapy (0.05 mg daily)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups (oral and transdermal)
Number of subjects: 45
Study: 14971862

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 36
Study: 11093452

Group type: COMPARATOR
Intervention: Motivated simulator group (financially incentivized to simulate FM)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal control group (healthy volunteers)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Chronic FM subjects
Number of subjects: 27

Group type: COMPARATOR
Intervention: Blinded examiners using American College of Rheumatology criteria for FM
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall study findings
Number of subjects: 27
Study: 9383183

Group type: EXPERIMENTAL
Intervention: 50 mg losartan (plus 12.5 mg hydrochlorothiazide if necessary)
Number of subjects: 898

Group type: COMPARATOR
Intervention: 5 mg amlodipine (increased to 10 mg if necessary)
Number of subjects: 898
Study: 1490530

Group type: EXPERIMENTAL
Intervention: Continuous bronchodilator treatment
Number of subjects: 144

Group type: COMPARATOR
Intervention: Symptomatic bronchodilator treatment
Number of subjects: 144
Study: 3883671

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 15

Group type: COMPARATOR
Intervention: meglumine iothalamate
Number of subjects: 15
Study: 31072935

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 29397354

Group type: EXPERIMENTAL
Intervention: Napabucasin 480 mg taken orally every 12 hours
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Napabucasin
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Napabucasin (in pSTAT3-positive patients)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo (in pSTAT3-positive patients)
Number of subjects: 282
Study: 27378185

Group type: EXPERIMENTAL
Intervention: Long-term use of antiepileptic drugs (AEDs)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Polytherapy >1 AED
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Age >12 years
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Indian ethnicity
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Sun exposure time 30-60 min/day
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Sun exposure time <30 min/day
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Female
Number of subjects: 244
Study: 24930587

Group type: EXPERIMENTAL
Intervention: Chlorophyll-a photodynamic therapy (8 treatment sessions over 4 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Light-emitting diode phototherapy (control)
Number of subjects: 24
Study: 22520135

Group type: EXPERIMENTAL
Intervention: RIX4414 (3 doses)
Number of subjects: 1773

Group type: EXPERIMENTAL
Intervention: RIX4414 (2 doses)
Number of subjects: 1773

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1773

Group type: EXPERIMENTAL
Intervention: RIX4414 (overall efficacy)
Number of subjects: 1773

Group type: EXPERIMENTAL
Intervention: RIX4414 (second year of life)
Number of subjects: 1773

Group type: EXPERIMENTAL
Intervention: RIX4414 (first year of life)
Number of subjects: 1773

Group type: EXPERIMENTAL
Intervention: RIX4414 (three-dose schedule)
Number of subjects: 1773
Study: 20623434

Group type: EXPERIMENTAL
Intervention: Seven‐eyelet lacings
Number of subjects: 14

Group type: COMPARATOR
Intervention: Regular six‐eyelet technique
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Individually chosen special seven‐eyelet lacings
Number of subjects: 14
Study: 17659990

Group type: COMPARATOR
Intervention: Music therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Butterbur root extract
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 15795719

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine infused over 15 minutes
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine infused over 60 minutes
Number of subjects: 180
Study: 12420826

Group type: EXPERIMENTAL
Intervention: Program of regular supplemental human interaction (20 min/d, 5 d/wk, for 8 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Premium diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Typical maintenance-type diet
Number of subjects: 40
Study: 10328384

Group type: EXPERIMENTAL
Intervention: Scleral suture fixation
Number of subjects: 153

Group type: COMPARATOR
Intervention: Out-of-the-bag implantation
Number of subjects: 153

Group type: COMPARATOR
Intervention: In-the-bag implantation
Number of subjects: 153
Study: 8787036

Group type: EXPERIMENTAL
Intervention: Long-acting haloperidol (LA HAL)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Oral administration of haloperidol
Number of subjects: 31
Study: 1659934

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitors
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 180
Study: 6356911

Group type: EXPERIMENTAL
Intervention: Fenbufen (Cinopal) at doses of 600 to 1,000 mg daily
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Fenbufen (Cinopal)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Aspirin, Indomethacin, Placebo
Number of subjects: 155
Study: 31436125

Group type: EXPERIMENTAL
Intervention: Mathematical model of synaptic plasticity in the SCN network
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T-cycles with periods within 2.5 to 3 h of the population period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low variability of periods between oscillators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater between-cell variability
Number of subjects: 0
Study: 28741785

Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg per day) from 11-14 until 36 weeks' gestation
Number of subjects: 25797

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25797

Group type: EXPERIMENTAL
Intervention: Combined first-trimester screening for preterm PE
Number of subjects: 25797
Study: 26911397

Group type: EXPERIMENTAL
Intervention: Adherence therapy (six sessions in addition to usual care)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual psychiatric care alone
Number of subjects: 134
Study: 24500453

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) - one pre and six postoperative sessions
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 57
Study: 22676459

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 19899321

Group type: EXPERIMENTAL
Intervention: noMR group (n = 40) - only an intubation dose of cisatracurium (0.15 mg kg(‐1)) was administered
Number of subjects: 80

Group type: COMPARATOR
Intervention: MR group (n = 40) - continuous infusion of muscle relaxant added to the intubation dose
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: noMR group (n = 40) - more remifentanil was used (p = 0.001)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both groups - post-operative characteristics and complication rates
Number of subjects: 80
Study: 17642451

Group type: EXPERIMENTAL
Intervention: Peak-flow based self-management (Group A, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment (Group B, n=30)
Number of subjects: 60
Study: 15100698

Group type: EXPERIMENTAL
Intervention: Ketamine at 50 ng/ml plasma concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketamine at 100 ng/ml plasma concentration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11246934

Group type: EXPERIMENTAL
Intervention: Anhydrous crystalline maltose (ACM) 200 mg lozenge, administered three times daily for 12 weeks (study Alpha)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Anhydrous crystalline maltose (ACM) 200 mg lozenge, administered three times daily for 24 weeks (study Omega)
Number of subjects: 119
Study: 9674458

Group type: EXPERIMENTAL
Intervention: Sparfloxacin, 400 mg on day 1, then 200 mg once daily for 10 days
Number of subjects: 798

Group type: COMPARATOR
Intervention: Ofloxacin, 400 mg twice daily for 10 days
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 798

Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 798
Study: 8033429

Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous immune globulin (IVIG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Induction chemotherapy and/or relapse
Number of subjects: 0
Study: 2735963

Group type: EXPERIMENTAL
Intervention: Small group intervention
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Home study intervention
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Both intervention models
Number of subjects: 374
Study: 29652544

Group type: EXPERIMENTAL
Intervention: Device-guided slow breathing (DGB) at 5 breaths/min (n = 13)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham device breathing at normal rates of 14 breaths/min (n = 10)
Number of subjects: 23
Study: 28577670

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 10921

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10921
Study: 26031292

Group type: EXPERIMENTAL
Intervention: Solar-simulated ultraviolet light (SSL) irradiation
Number of subjects: 24
Study: 23642943

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (2 g per day, single dosage of two 1 g pearls)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo (2 placebo soft gels)
Number of subjects: 124
Study: 21091683

Group type: EXPERIMENTAL
Intervention: Topical nadifloxacin 1% cream
Number of subjects: 86

Group type: COMPARATOR
Intervention: Topical erythromycin 4% gel
Number of subjects: 86
Study: 18206946

Group type: EXPERIMENTAL
Intervention: Alarm treatment following pretreatment with antimuscarinics and/or holding exercises
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group receiving just alarm treatment
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Groups A and B with holding exercises
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Previous treatment
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Age younger than 8 years
Number of subjects: 149
Study: 16685128

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 2330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2330
Study: 15335092

Group type: EXPERIMENTAL
Intervention: 10% Carbamide peroxide (CP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 15% Carbamide peroxide (CP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 90
Study: 21407958

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 9333973

Group type: EXPERIMENTAL
Intervention: Orthopedic Horseback‐Riding‐Therapy (OHRT)
Number of subjects: 16
Study: 8500515

Group type: EXPERIMENTAL
Intervention: 2 mg bumethanide at 0800 and 1200 (treatment 1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1 mg bumethanide at 0800, 1200, 1800, 2200 (treatment 2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 mg bendroflumethiazide at 0800 and 1800 (treatment 3)
Number of subjects: 8
Study: 3014018

Group type: EXPERIMENTAL
Intervention: IFN‐beta ser
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 29615003

Group type: EXPERIMENTAL
Intervention: DNR + Ara-C (Ara-C group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: DNR (no-Ara-C group)
Number of subjects: 66
Study: 27584567

Group type: EXPERIMENTAL
Intervention: Intravenous β-blockers
Number of subjects: 1149
Study: 24215858

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Omega-3
Number of subjects: 355

Group type: COMPARATOR
Intervention: Usual Activity (Control)
Number of subjects: 355
Study: 22638012

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 20815080

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisolone (PDN)
Number of subjects: 0
Study: 19128246

Group type: EXPERIMENTAL
Intervention: Doxycycline-releasing stents
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo stents
Number of subjects: 10